Light-Induced Protein Degradation with Photocaged PROTACs

Xue, Gang, Wang, Kun, Zhou, Danli, Zhong, Hanbing, Pan, Zhengying·2019·Journal of the American Chemical Society
DOI 10.1021/jacs.9b06422

Cited by (383)

Items 101–200 of 383

  1. Unconventional PROTACs for Targeted Protein Degradation in Cancer Therapy
    Xu Zhang, Zhangzhi Song, Xinyu Zhang, Jianhua Zou, Guocan Yu, Xiaoyuan Shawn Chen, Sheng Wang · 2025 · Angewandte Chemie International Edition
  2. Recent advances in targeted protein degraders as potential therapeutic agents
    Na Yang, Bo Kong, Zhaohong Zhu, Fei Huang, Liliang Zhang, Tao Lu, Yadong Chen, Yanmin Zhang, Yulei Jiang · 2023 · Molecular Diversity
  3. Protein degradation: a novel computational approach to design protein degrader probes for main protease of SARS-CoV-2
    Muhammed Shaheer, Ravi Singh, Masilamani Elizabeth Sobhia · 2021 · Journal of Biomolecular Structure and Dynamics
  4. Controlling PROTACs with Light
    Shreya Verma, Debasish Manna · 2020 · ChemMedChem
  5. Selective degradation of BRD4 suppresses lung cancer cell proliferation using GSH-responsive PROTAC precursors
    Heli Fan, Zhili Zhou, Dehao Yu, Jing Fang Sun, Luo Wang, Yuanyuan Jia, Junyu Tian, Wenyi Mi, Huabing Sun · 2023 · Bioorganic Chemistry
  6. Advancements in delivery Systems for Proteolysis-Targeting Chimeras (PROTACs): Overcoming challenges and expanding biomedical applications
    Yawei Yu, Weitong Hu, Yihua Xu, Hong-bin Xu, Jian-Qing Gao · 2025 · Journal of Controlled Release
  7. Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions
    Gang Fan, Shilin Chen, Qingping Zhang, Na Yu, Ziyang Shen, Zhaoji Liu, Weiming Guo, Zhi‐Han Tang, Jing Yang, Miao Liu · 2025 · MedComm
  8. PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs
    María Maneiro, Elena De Vita, Daniel Conole, Cyrille S. Kounde, Qisi Zhang, Edward W. Tate · 2021 · Progress in medicinal chemistry
  9. Options to Improve the Action of PROTACs in Cancer: Development of Controlled Delivery Nanoparticles
    Alberto Juan, María del Mar Noblejas‐López, María Arenas-Moreira, Carlos Alonso‐Moreno, Alberto Ocaña · 2022 · Frontiers in Cell and Developmental Biology
  10. Design and linkage optimization of ursane-thalidomide-based PROTACs and identification of their targeted-degradation properties to MDM2 protein
    Qi, Zhiwen, Yang, Guliang, Deng, Tao, Wang, Jianmin, Zhou, Hao, Popov, Sergey A., Shults, Elvira E., Wang, Chengzhang · 2021 · Bioorganic Chemistry
  11. Cooperatively designed aptamer-PROTACs for spatioselective degradation of nucleocytoplasmic shuttling protein for enhanced combinational therapy
    Ran Liu, Zheng Liu, Mohan Chen, Hang Xing, Penghui Zhang, Jingjing Zhang · 2023 · Chemical Science
  12. Photorelease of Pyridines Using a Metal‐Free Photoremovable Protecting Group
    Xiao‐Jun Tang, Yayun Wu, Rong Zhao, Xiaolong Kou, Zaizai Dong, Wei Zhou, Zhen Zhang, Weihong Tan, Xiaohong Fang · 2020 · Angewandte Chemie International Edition
  13. Light-Controllable PROTACs for Temporospatial Control of Protein Degradation
    Jing Liu, Yunhua Peng, Wenyi Wei · 2021 · Frontiers in Cell and Developmental Biology
  14. Targeted protein degradation at the host–pathogen interface
    Christoph Grohmann, Danushka S. Marapana, Gregor Ebert · 2021 · Molecular Microbiology
  15. Novel Design Strategies to Enhance the Efficiency of Proteolysis Targeting Chimeras
    Chunlong Zhao, Frank J. Dekker · 2022 · ACS Pharmacology & Translational Science
  16. Dual‐Programmable Semiconducting Polymer NanoPROTACs for Deep‐Tissue Sonodynamic‐Ferroptosis Activatable Immunotherapy
    Fengshuo Wang, Guoqiang Dong, Mengbin Ding, Ningyue Yu, Chunquan Sheng, Jingchao Li · 2023 · Small
  17. A comprehensive review of BET-targeting PROTACs for cancer therapy
    Xiaoli Zhou, Fang Zhao, Yong-Tao Xu, Yuanyuan Guan, Tong Yu, Yizhe Zhang, Ying‐Chao Duan, Yuan Zhao · 2022 · Bioorganic & Medicinal Chemistry
  18. Chemically induced degradation of epigenetic targets
    Md Kabir, Xufen Yu, H. Ümit Kanıskan, Jian Jun Jin · 2023 · Chemical Society Reviews
  19. Designing an eEF2K-Targeting PROTAC small molecule that induces apoptosis in MDA-MB-231 cells
    Yao Liu, Yongqi Zhen, Guan Wang, Gaoxia Yang, Leilei Fu, Bo Liu, Liang Ouyang · 2020 · European Journal of Medicinal Chemistry
  20. Design, synthesis and biological evaluation of the tumor hypoxia-activated PROTACs bearing caged CRBN E3 ligase ligands
    Weiyan Cheng, Shasha Li, Siyuan Han, Ruoyang Miao, Suhua Wang, Chunxia Liu, Wei Han, Xin Tian, Xiaojian Zhang · 2023 · Bioorganic & Medicinal Chemistry
  21. E3 ubiquitin ligases and deubiquitinases in colorectal cancer: Emerging molecular insights and therapeutic opportunities
    Sunny Kumar, Malini Basu, Mrinal K. Ghosh · 2024 · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
  22. Precision-engineered PROTACs minimize off-tissue effects in cancer therapy
    Jianghua Shi, Luo Wang, Xuanwei Zeng, Chengzhi Xie, Zhaowei Meng, Anahit Campbell, Lulu Wang, Heli Fan, Huabing Sun · 2024 · Frontiers in Molecular Biosciences
  23. Frontiers in PROTACs
    Gregory R. Hughes, Ashley P. Dudey, Andrew M. Hemmings, Andrew Chantry · 2021 · Drug Discovery Today
  24. Targeted Protein Degradation through Fast Optogenetic Activation and Its Application to the Control of Cell Signaling
    Amy Ryan, Jihe Liu, Alexander Deiters · 2021 · Journal of the American Chemical Society
  25. The Ubiquitin–Proteasome System in Tumor Metabolism
    Jie Wang, Yuandi Xiang, Mengqi Fan, Shizhen Fang, Qingquan Hua · 2023 · Cancers
  26. PROTACs as Therapeutic Modalities for Drug Discovery in Castration-Resistant Prostate Cancer
    Ling‐Yu Wang, Chiu-Lien Hung, Tsan-Chun Wang, Hung‐Chih Hsu, Hsing-Jien Kung, Kwang‐Huei Lin · 2024 · The Annual Review of Pharmacology and Toxicology
  27. Photocontrolled activation of small molecule cancer therapeutics
    Martin Michael Dcona, Koushambi Mitra, Matthew C. T. Hartman · 2020 · RSC Medicinal Chemistry
  28. Progress of small molecules for targeted protein degradation: PROTACs and other technologies
    Hongyi Zhao, Minhang Xin, San‐Qi Zhang · 2023 · Drug Development Research
  29. Current strategies for improving limitations of proteolysis targeting chimeras
    Chunlan Pu, Shirui Wang, Lei Liu, Zhonghui Feng, Hongjia Zhang, Qianyuan Gong, Yueshan Sun, Yuanbiao Guo, Rui Li · 2022 · Chinese Chemical Letters
  30. Tandem‐Activatable PROTAC Prodrug for Tumor Biomarker‐Driven Near‐Infrared Opto‐Proteolysis
    Xiaoyan Lu, Xiaoning Wang, Hanwen Liao, Baitong Sha, Yan Zhang, Jinbo Li · 2025 · Angewandte Chemie International Edition
  31. Discovery of novel anti-angiogenesis agents. Part 11: Development of PROTACs based on active molecules with potency of promoting vascular normalization
    Yuanyuan Shan, Ru Si, Jin Wang, Qingqing Zhang, Jing Li, Yuexiang Ma, Jie Zhang · 2020 · European Journal of Medicinal Chemistry
  32. Progress of proteolysis-targeting chimeras (PROTACs) delivery system in tumor treatment
    Lianlian Fan, Weifang Tong, Anhui Wei, Xupeng Mu · 2024 · International Journal of Biological Macromolecules
  33. Protacs in cancer therapy: mechanisms, design, clinical trials, and future directions
    Akash Vikal, Rashmi Maurya, Brij Bihari Patel, Rajeev Kr. Sharma, Preeti Patel, Umesh Kumar Patil, Balak Das Kurmi · 2024 · Drug Delivery and Translational Research
  34. Enzyme‐Activated Orthogonal Proteolysis Chimeras for Tumor Microenvironment‐Responsive Immunomodulation
    Caixia Sun, Songhan Liu, Jun Wei Lau, Hanyu Yang, Yun Chen, Bengang Xing · 2025 · Angewandte Chemie International Edition
  35. Indolequinone-Based Hypoxia-Activated Proteolysis Targeting Chimeras Selectively Degrade BRD4 in Hypoxic Cancer Cells
    M. Teresa Serafini, Sophie A. Twigger, George Delfas, Maxim Mallerman, Elliot P. Bailey, Ewen D. D. Calder, Ester M. Hammond, Stuart J. Conway · 2025 · Journal of the American Chemical Society
  36. Emerging TACnology: Heterobifunctional Small Molecule Inducers of Targeted Posttranslational Protein Modifications
    Pascal Heitel · 2023 · Molecules
  37. Discovery of estrogen receptor α targeting caged hypoxia-responsive PROTACs with an inherent bicyclic skeleton for breast cancer treatment
    Baohua Xie, Bin Xu, Lilan Xin, Yizhou Wei, Xinyi Guo, Chune Dong · 2023 · Bioorganic Chemistry
  38. Glutathione-responsive PROTAC for targeted degradation of ERα in breast cancer cells
    Z. Zhou, Heli Fan, Dehao Yu, Fengying Shi, Qianqian Li, Zhenjian Zhang, Xiaolu Wang, Xuejun Zhang, Cheng Dong, Huabing Sun et al. · 2023 · Bioorganic & Medicinal Chemistry
  39. PROTAC unleashed: Unveiling the synthetic approaches and potential therapeutic applications
    Narayanaperumal Pravin, Krzysztof Jóźwiak · 2024 · European Journal of Medicinal Chemistry
  40. PROTAC delivery in tumor immunotherapy: Where are we and where are we going?
    Yiyang Li, Yike Wu, Sihan Gao, Tao Sun, Chen Jiang · 2024 · Journal of Controlled Release
  41. Strategy and Design of In Situ Activated Protein Hydrolysis Targeted Chimeras
    Mei-Yu Lv, Da‐Yong Hou, Shaowei Liu, Dong‐Bing Cheng, Haoran Wang · 2024 · ACS Nano
  42. PROTAC Technology as a New Tool for Modern Pharmacotherapy
    Natalia Kubryń, Łukasz Fijałkowski, Jacek Nowaczyk, Amer Jamil, Alicja Nowaczyk · 2025 · Molecules
  43. Photopharmacology of Proteolysis-Targeting Chimeras: A New Frontier for Drug Discovery
    Shenxin Zeng, Hongjie Zhang, Zhengrong Shen, Wenhai Huang · 2021 · Frontiers in Chemistry
  44. More than Toxins—Current Prospects in Designing the Next Generation of Antibody Drug Conjugates
    Jonathan Schwach, Mustafa Abdellatif, Andreas Stengl · 2022 · Frontiers in Bioscience-Landmark
  45. PROTACs in gastrointestinal cancers
    Yu Chen, Qingfan Yang, Jinrun Xu, Liyao Tang, Yan Zhang, Fukuan Du, Yueshui Zhao, Xu Wu, Mingxing Li, Jing Shen et al. · 2022 · Molecular Therapy — Oncolytics
  46. Optochemical Control of Protein Degradation
    Peng Wu, Debasish Manna · 2020 · ChemBioChem
  47. Integrating Proteolysis‐Targeting Chimeras (PROTACs) with Delivery Systems for More Efficient and Precise Targeted Protein Degradation
    Jiachan Lin, Zirui Chen, Dan Zhang, Nan Zhang, Hongzhong Chen, Dong‐Sheng Guo · 2025 · Macromolecular Rapid Communications
  48. The Potential of Proteolytic Chimeras as Pharmacological Tools and Therapeutic Agents
    Bernat Coll-Martínez, Antonio Delgado, Bernat Crosas · 2020 · Molecules
  49. The Construction of Polyphotocage Platform for Anticancer Photochemotherapy
    Maomao He, Ran Wang, Ruifeng Zhang, Pengcheng Miao, Peiyuan Wang, Zhiyong Wei, Xuefei Leng, Yang Li, Jiangli Fan, Xiaojun Peng et al. · 2023 · Advanced Functional Materials
  50. A programmable targeted protein-degradation platform for versatile applications in mammalian cells and mice
    Xiaoding Ma, Jianli Yin, Longliang Qiao, Hang Wan, Xingwan Liu, Yang Zhou, Jiali Wu, Lingxue Niu, Min Wu, Xinyi Wang et al. · 2024 · Molecular Cell
  51. Conditional PROTAC: Recent Strategies for Modulating Targeted Protein Degradation
    Junhyeong Yim, Jun‐Young Park, Gabin Kim, Hyung Ho Lee, Jin Soo Chung, Ala Jo, Minseob Koh, Jongmin Park · 2024 · ChemMedChem
  52. PROTAC: Novel degradable approach for different targets to treat breast cancer
    Zhenjie Wang, Siyao Che, Zhiqiang Yu · 2024 · European Journal of Pharmaceutical Sciences
  53. Prodrug Strategy for PROTACs: High Efficiency and Low Toxicity
    Yuqing Li, Yongcheng Guo, Simin Ma, Baobang Long, Rui Kong, Xin Huang, Kun Zhao, Ying Zhi · 2025 · ACS Omega
  54. Rational design of the linkers in targeting chimeras
    Yiping Duan, Michelle Y. Cai, Jinyi Xu, Quanyin Hu · 2025 · Chemical Science
  55. PhotoPROTACs: A Novel Biotechnology for Cancer Treatment
    Zhiwei Peter Wang, Yi Liu, Xueqiong Zhu · 2020 · Trends in Cell Biology
  56. Remodeling the Physicochemical and Pharmacokinetic Properties of PROTAC via Lipid Nanodisks for Cancer Therapy
    Meichen Pan, Chunrong Yang, Zhongliang Fu, Yuchen Yang, Ying Zhuo, Hongwei Hou, Jinghong Li · 2025 · Advanced Science
  57. Enzyme-Activated Sugar-Coated Bifunctional Degraders
    Qian Zhu, Gerhard Fischer, S V Cheng, N. Connor Payne, Daniel Peter, Alison C. Mody, Silvia Arce-Solano, Dacheng Shen, Zhi Lin, Ralph Mazitschek et al. · 2025 · Journal of the American Chemical Society
  58. Proteolysis-Targeting Chimera (PROTAC): Is the Technology Looking at the Treatment of Brain Tumors?
    Ludovica Lospinoso Severini, Francesca Bufalieri, Paola Infante, Lucia Di Marcotullio · 2022 · Frontiers in Cell and Developmental Biology
  59. Bioorthogonally Activatable Autophagy-Tethering Compounds for Aptamer-Guided Mitochondrial Degradation
    Mengmeng Liu, Zhenqi Liu, Geng Qin, Jinsong Ren, Xiaogang Qu · 2023 · Nano Letters
  60. Recent Advances in Optically Controlled PROTAC
    Muzi Ouyang, Ying Ning Feng, Hui Chen, Yanping Liu, Chunyan Tan, Ying Ching Tan · 2023 · Bioengineering
  61. Controlled bioorthogonal activation of Bromodomain-containing protein 4 degrader by co-delivery of PROTAC and Pd-catalyst for tumor-specific therapy
    Zhiyao Li, Tai‐Bai Jiang, Yuan Xu, Bowen Li, Chongzhi Wu, Yecheng Li, Yong Ping Huang, Xin Xie, Weidong Pan, Ping Yuan · 2024 · Journal of Controlled Release
  62. Finding a needle in the haystack: ADME and pharmacokinetics/pharmacodynamics characterization and optimization towards orally available bifunctional protein degraders
    Giulia Apprato, Giulia Caron, Gauri S. Deshmukh, Diego Garcia-Jimenez, Robin Thomas Ulrich Haid, Andy Pike, Andreas Reichel, Caroline Rynn, Donglu Zhang, Matthias Wittwer · 2025 · Expert Opinion on Drug Discovery
  63. Synthesis, biological evaluation and clinical trials of Cereblon-based PROTACs
    André T. S. Vicente, Sara P. S. P. Moura, Jorge A. R. Salvador · 2025 · Communications Chemistry
  64. Targeted Degradation of Bromodomain-Containing Protein 4 Enabled by Reactive Oxygen Species–Activatable NanoPROTACs as an Efficient Strategy to Reverse Liver Fibrosis in Chronic Liver Injury
    Tao Bi, Pan Liang, Qixin Zhao, Jiao Wu, Yanan Zhou, Yunke Xu, Xuehui Fan, Guoqiang Yang, Qin Sun, Wei Ren et al. · 2025 · Journal of Medicinal Chemistry
  65. Light-Activating PROTACs in Cancer: Chemical Design, Challenges, and Applications
    Arvind Negi, Kavindra Kumar Kesari, Anne Sophie Voisin‐Chiret · 2022 · Applied Sciences
  66. Recent advances in epigenetic proteolysis targeting chimeras (Epi-PROTACs)
    Daniela Tomaselli, Nicola Mautone, Antonello Mai, Dante Rotili · 2020 · European Journal of Medicinal Chemistry
  67. Modular Development of Enzyme-Activatable Proteolysis Targeting Chimeras for Selective Protein Degradation and Cancer Targeting
    Yanchi Chen, Lina Zhang, Lincheng Fang, Chengjie Chen, Dong Zhang, Tao Peng · 2024 · JACS Au
  68. Hydrogen Peroxide‐Inducible PROTACs for Targeted Protein Degradation in Cancer Cells
    Dehao Yu, Heli Fan, Zhili Zhou, Ying Zhang, Jing Sun, Luo Wang, Yuanyuan Jia, Junyu Tian, Anahit Campbell, Wenyi Mi et al. · 2023 · ChemBioChem
  69. Development of visible-light-activatable photocaged PROTACs
    Weizhi Weng, Gang Xue, Zhengying Pan · 2023 · European Journal of Medicinal Chemistry
  70. Application of PROTACs in target identification and validation
    Yang Liu, Jing Yu Liang, Rui Zhu, Yueying Yang, Yali Wang, Wenyi Wei, Hua Li, Lixia Chen · 2024 · Acta Materia Medica
  71. Proteolysis-targeting chimeras: A promising technique in cancer therapy for gaining insights into tumor development
    Moyang Lv, Weichao Hu, Shengwei Zhang, Lijiao He, Changjiang Hu, Shiming Yang · 2022 · Cancer Letters
  72. Targeting micro-environmental pathways by PROTACs as a therapeutic strategy
    Jing Liu, Yunhua Peng, Hiroyuki Inuzuka, Wenyi Wei · 2022 · Seminars in Cancer Biology
  73. New techniques and strategies in drug discovery (2020–2024 update)
    Qijie Gong, Jian Hua Song, Yihui Song, Kai Tang, Panpan Yang, Xiao Wang, Min Zhao, Liang Ouyang, Li Rao, Bin Yu et al. · 2024 · Chinese Chemical Letters
  74. Application of Hypoxia-Activated Prodrugs in Tumor Therapy: Design Strategies and Perspectives
    Shengyu Liu, Mijia Zhang, Xiangxi Sun, Peng George Wang, Guogang Zhang, Wenyan Li · 2025 · Journal of Medicinal Chemistry
  75. Photodynamic enhancement of PROTAC prodrug activation in hypoxic tumors
    Zhongliang Fu, Chunrong Yang, Yuchen Yang, Meichen Pan, Hongwei Hou, Jinghong Li · 2025 · Acta Pharmaceutica Sinica B
  76. Proteolysis-targeting chimeras in biotherapeutics: Current trends and future applications
    Qiong Li, Li Zhou, Siyuan Qin, Zhao Huang, Bowen Li, Bowen Li, Mei Yang, Edouard Collins Nice, Huili Zhu, Canhua Huang · 2023 · European Journal of Medicinal Chemistry
  77. Discovery of X10g as a selective PROTAC degrader of Hsp90α protein for treating breast cancer
    Qingna Jiang, Minghai Fu, Yuanling Tang, Ge Li, Guihui Tu, Xinhua Wu, Qiurong Wu, Xiuwang Huang, Jianhua Xu, Yang Liu et al. · 2023 · European Journal of Medicinal Chemistry
  78. Photoactive Bifunctional Degraders: Precision Tools To Regulate Protein Stability
    Cyrille S. Kounde, Edward W. Tate · 2020 · Journal of Medicinal Chemistry
  79. PHOTACs Enable Optical Control of Protein Degradation
    Martin Reynders, Dirk H. Trauner · 2021 · Methods in molecular biology
  80. Nanotechnology‐Enabled Targeted Protein Degradation for Cancer Therapeutics
    Wutong Zhao, Yongbin Jiang, Xiufen Li, Hai Wang · 2024 · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology
  81. Emerging Strategies in Smart Nano-PROTAC for Stimuli-Responsive Protein Degradation and Precision Cancer Therapy
    Zhimin Weng, Jiaojiao Yu, Yuanrong Liao, Yuanyuan Zhang, Changmai Chen, Wei Chen · 2025 · Nano Biomedicine and Engineering
  82. Restraining the power of Proteolysis Targeting Chimeras in the cage: A necessary and important refinement for therapeutic safety
    Renshuai Zhang, Songbo Xie, Jie Ran, Te Li · 2024 · Journal of Cellular Physiology
  83. Targeted Protein Degradation as a Promising Tool for Epigenetic Upregulation of Fetal Hemoglobin
    Thijs C. J. Verheul, Van Tuan Trinh, Olalla Vázquez, Sjaak Philipsen · 2020 · ChemMedChem
  84. Light induced spiking of proteinoids
    Panagiotis Mougkogiannis, Andrew Adamatzky · 2023 · Biosystems
  85. Advancements in Proteolysis Targeting Chimeras for Targeted Therapeutic Strategies in Alzheimer’s Disease
    Qiuzhi Zhou, Weixia Wang, Chunchu Deng · 2025 · Molecular Neurobiology
  86. Targeted protein degradation technologies: Emerging mechanisms and nano-based innovations
    Mingge Hou, Runze Zhao, Shenghui Wang, Bing Jiang, Xiyun Yan · 2025 · Nano Research
  87. Recent Advances in the Development of Pro-PROTAC for Selective Protein Degradation
    Fady T. Hakem, Ahmad Abdelwaly, Reem Alshaman, Abdullah Alattar, Fawaz E. Alanazi, Sawsan A. Zaitone, Mohamed A. Helal · 2025 · Pharmaceutics
  88. Targeting bacterial degradation machinery as an antibacterial strategy
    Radoslav Petkov, Amy H. Camp, Rivka Leah Isaacson, James H. Torpey · 2023 · Biochemical Journal
  89. Conquering PROTAC molecular design and drugability
    Ritesh P. Bhole, Sonali Labhade, Shailendra Shivaji Gurav · 2025 · Bioanalysis
  90. Proteolysis Targeting Chimeric Molecules: Tuning Molecular Strategies for a Clinically Sound Listening
    Federica Pedrucci, Claudia Pappalardo, Giovanni Marzaro, Nicola Ferri, Alberto Ferlin, Luca De Toni · 2022 · International Journal of Molecular Sciences
  91. Cell-Specific Degradation of Histone Deacetylase Using Warhead-Caged Proteolysis Targeting Chimeras
    Qi Jia, Yue Zhang, Feng Liu, Wanrong Dong, Lei Zhu, Fenglin Wang, Jian‐Hui Jiang · 2023 · Analytical Chemistry
  92. Chimera induced protein degradation: PROTACs and beyond
    Lina Yin, Qingzhong Hu · 2020 · European Journal of Medicinal Chemistry
  93. Smartphone-Manipulated Mild-Temperature Photothermal Control of the TfR-LYTAC Platform for Tumor Treatment
    Chunqin Shi, Ling‐Yan Su, Wen Xu, Shuangping Wang, Yu Cao, Mengyu Yao, Xiao Wang, Fei Liu, Guangjun Nie, Hejiang Zhou · 2025 · Nano Letters
  94. Precise Modulation of Protein Degradation by Smart PROTACs
    Junfei Cheng, Guoqiang Dong, Wei Wang, Chunquan Sheng · 2024 · ChemBioChem
  95. Recent Advances in the Design and Development of Anticancer Molecules based on PROTAC Technology
    Zere Mukhamejanova, Yichen Tong, Qi Xiang, Fang Xu, Jiyan Pang · 2020 · Current Medicinal Chemistry
  96. PROTAC: A Novel Technology for Drug Development**
    Jie Li, Jie‐Qing Liu · 2020 · ChemistrySelect
  97. Targeting Oncoproteins for Degradation by Small Molecule-Based Proteolysis-Targeting Chimeras (PROTACs) in Sex Hormone-Dependent Cancers
    Li Liu, Lihong Shi, Zhaodi Wang, Jun Zeng, Yue Wang, Hongtao Xiao, Yongxia Zhu · 2022 · Frontiers in Endocrinology
  98. Smart PROTACs Enable Controllable Protein Degradation for Precision Cancer Therapy
    Lixia Chen, Xinqiang Wan, Xiangxiang Shan, Wenzhang Zha, Rengen Fan · 2022 · Molecular Diagnosis & Therapy
  99. Photomodulation Approaches to Overcome Antimicrobial Resistance
    Sofia N. Sarabando, Andreia Palmeira, Emı́lia Sousa, M. Amparo F. Faustino, Carlos J. P. Monteiro · 2023 · Pharmaceuticals
  100. Light-inducible protein degradation in E. coli with the LOVdeg tag
    Nathan Tague, Cristian Coriano-Ortiz, Michael B. Sheets, Mary J. Dunlop · 2023 · eLife